Articles

A new bioanalytical lab being opened by Ardena at the site is expected to be operational by the third quarter of 2025.

Ardena Acquires Catalent Drug Product Manufacturing Facility in New Jersey

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Hood, a pioneer of systems biology and systems medicine, shared his personal interest in starting a new peptide-based, informational-driven pharmaceutical company that would address wellness and longevity.

Systems Biology Pioneer Lee Hood Talks Precision Medicine, AI in Health, and the Next Paradigm Shift 

The transaction is expected to enhance Jabil’s development and commercial production of auto-injectors, pen injectors, inhalers, and on-body pumps.

Jabil Completes Acquisition of Pharmaceutics International, Inc.

The tariffs President Trump wants to levy against Canada and Mexico are on hold, for now, but China has already announced it intends to proceed with retaliatory tariffs against the US.

Pharmaceutical Industry Responds to Proposed Trump Administration Tariffs

While FMS has specialized in the design, installation, and maintenance of environmental monitoring systems, Trescal’s focus has been on calibration and metrology services.

Trescal Acquires Facility Monitoring Systems to Bolster UK Contamination Control Services Market

The company is recalling one lot of Fentanyl Transdermal System 25 mcg/h transdermal patches because of possible multi-stacking of patches.

Alvogen Recalls Fentanyl Transdermal System

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Bio/pharma companies have a lot to consider when tackling social media communications, especially within Europe.

The Social Media Code

Another eight medications already authorized in the EU were recommended for extensions of various indications.

EMA Recommends Eight New Medicines for Approval in January 

Mike Hennessy Jr. is the Chairman and CEO of 

If the conditions prove optimal, 2025 could be a prosperous year for bio/pharma business deals.

Dealmaking on the Rise?

Siegfried Schmitt, PhD, is Vice President Technical at Parexel International, Siegfried.Schmitt@parexel.com.

AI regulations in healthcare are rapidly evolving, and one should consult with regulatory subject matter experts, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.

News